Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status

References

• Evans AJ, Gallie BL, Jewett MA, Pond GR, Vandezande K, Underwood J, et al. Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. Am J Pathol 2004; 164:285 - 93; http://dx.doi.org/10.1016/S0002-9440(10)63118-5; PMID: 14695341
   PubMed Web of Science ®Google Scholar
• Orlic M, Spencer CE, Wang L, Gallie BL. Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 2006; 45:72 - 82; http://dx.doi.org/10.1002/gcc.20263; PMID: 16180235
   PubMed Web of Science ®Google Scholar
• Kappes F, Burger K, Baack M, Fackelmayer FO, Gruss C. Subcellular localization of the human proto-oncogene protein DEK. J Biol Chem 2001; 276:26317 - 23; http://dx.doi.org/10.1074/jbc.M100162200; PMID: 11333257
   PubMed Web of Science ®Google Scholar
• Waldmann T, Baack M, Richter N, Gruss C. Structure-specific binding of the proto-oncogene protein DEK to DNA. Nucleic Acids Res 2003; 31:7003 - 10; http://dx.doi.org/10.1093/nar/gkg864; PMID: 14627833
   PubMed Web of Science ®Google Scholar
• von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A, et al. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992; 12:1687 - 97; PMID: 1549122
   PubMed Web of Science ®Google Scholar
• Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S, et al. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 1999; 59:4990 - 6; PMID: 10519413
   PubMed Web of Science ®Google Scholar
• Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, et al. The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett 2000; 156:191 - 8; http://dx.doi.org/10.1016/S0304-3835(00)00462-6; PMID: 10880769
   PubMed Web of Science ®Google Scholar
• Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M, et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006; 5:1202 - 7; http://dx.doi.org/10.4161/cc.5.11.2801; PMID: 16721057
   PubMed Web of Science ®Google Scholar
• Wu Q, Li Z, Lin H, Han L, Liu S, Lin Z. DEK overexpression in uterine cervical cancers. Pathol Int 2008; 58:378 - 82; http://dx.doi.org/10.1111/j.1440-1827.2008.02239.x; PMID: 18477217
   PubMed Web of Science ®Google Scholar
• Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS, et al. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 2009; 69:6405 - 13; http://dx.doi.org/10.1158/0008-5472.CAN-09-1063; PMID: 19679545
   PubMed Web of Science ®Google Scholar
• Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R, et al. Clinicopathological significance of DEK overexpression in serous ovarian tumors. Pathol Int 2009; 59:443 - 7; http://dx.doi.org/10.1111/j.1440-1827.2009.02392.x; PMID: 19563407
   PubMed Web of Science ®Google Scholar
• Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, et al. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene 2010; 29:4671 - 81; http://dx.doi.org/10.1038/onc.2010.217; PMID: 20543864
   PubMed Web of Science ®Google Scholar
• Szer IS, Sierakowska H, Szer W. A novel autoantibody to the putative oncoprotein DEK in pauciarticular onset juvenile rheumatoid arthritis. J Rheumatol 1994; 21:2136 - 42; PMID: 7869324
   PubMed Web of Science ®Google Scholar
• Dong X, Michelis MA, Wang J, Bose R, DeLange T, Reeves WH. Autoantibodies to DEK oncoprotein in a patient with systemic lupus erythematosus and sarcoidosis. Arthritis Rheum 1998; 41:1505 - 10; http://dx.doi.org/10.1002/1529-0131(199808)41:8<1505::AID-ART23>3.0.CO;2-N; PMID: 9704652
   PubMed Web of Science ®Google Scholar
• Alexiadis V, Waldmann T, Andersen J, Mann M, Knippers R, Gruss C. The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev 2000; 14:1308 - 12; PMID: 10837023
   PubMed Web of Science ®Google Scholar
• Campillos M, García MA, Valdivieso F, Vázquez J. Transcriptional activation by AP-2alpha is modulated by the oncogene DEK. Nucleic Acids Res 2003; 31:1571 - 5; http://dx.doi.org/10.1093/nar/gkg247; PMID: 12595566
   PubMed Web of Science ®Google Scholar
• Sitwala KV, Mor-Vaknin N, Markovitz DM. Minireview: DEK and gene regulation, oncogenesis and AIDS. Anticancer Res 2003; 23:3A 2155 - 8; PMID: 12894590
   PubMedGoogle Scholar
• Kappes F, Scholten I, Richter N, Gruss C, Waldmann T. Functional domains of the ubiquitous chromatin protein DEK. Mol Cell Biol 2004; 24:6000 - 10; http://dx.doi.org/10.1128/MCB.24.13.6000-6010.2004; PMID: 15199153
   PubMed Web of Science ®Google Scholar
• Soares LM, Zanier K, Mackereth C, Sattler M, Valcárcel J. Intron removal requires proofreading of U2AF/3′ splice site recognition by DEK. Science 2006; 312:1961 - 5; http://dx.doi.org/10.1126/science.1128659; PMID: 16809543
   PubMed Web of Science ®Google Scholar
• Mor-Vaknin N, Punturieri A, Sitwala K, Faulkner N, Legendre M, Khodadoust MS, et al. The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol 2006; 26:9484 - 96; http://dx.doi.org/10.1128/MCB.01030-06; PMID: 17030615
   PubMed Web of Science ®Google Scholar
• Gamble MJ, Fisher RP. SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat Struct Mol Biol 2007; 14:548 - 55; http://dx.doi.org/10.1038/nsmb1248; PMID: 17529993
   PubMed Web of Science ®Google Scholar
• Kappes F, Fahrer J, Khodadoust MS, Tabbert A, Strasser C, Mor-Vaknin N, et al. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol 2008; 28:3245 - 57; http://dx.doi.org/10.1128/MCB.01921-07; PMID: 18332104
   PubMed Web of Science ®Google Scholar
• Kim DW, Chae JI, Kim JY, Pak JH, Koo DB, Bahk YY, et al. Proteomic analysis of apoptosis related proteins regulated by proto-oncogene protein DEK. J Cell Biochem 2009; 106:1048 - 59; http://dx.doi.org/10.1002/jcb.22083; PMID: 19229864
   PubMed Web of Science ®Google Scholar
• Sammons M, Wan SS, Vogel NL, Mientjes EJ, Grosveld G, Ashburner BP. Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene. J Biol Chem 2006; 281:26802 - 12; http://dx.doi.org/10.1074/jbc.M600915200; PMID: 16829531
   PubMed Web of Science ®Google Scholar
• Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 2006; 26:7506 - 19; http://dx.doi.org/10.1128/MCB.00430-06; PMID: 16894028
   PubMed Web of Science ®Google Scholar
• Secchiero P, Voltan R, di Iasio MG, Melloni E, Tiribelli M, Zauli G. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. Clin Cancer Res 2010; 16:1824 - 33; http://dx.doi.org/10.1158/1078-0432.CCR-09-3031; PMID: 20215548
   PubMed Web of Science ®Google Scholar
• Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Münger K, et al. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol 2005; 79:14309 - 17; http://dx.doi.org/10.1128/JVI.79.22.14309-14317.2005; PMID: 16254365
   PubMed Web of Science ®Google Scholar
• Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, Balsitis SJ, et al. DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol 2009; 174:71 - 81; http://dx.doi.org/10.2353/ajpath.2009.080330; PMID: 19036808
   PubMed Web of Science ®Google Scholar
• Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA, et al. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res 2009; 69:1792 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-2304; PMID: 19223548
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999; 17:399 - 408; PMID: 10458259
   PubMed Web of Science ®Google Scholar
• Aalto Y, El-Rifa W, Vilpo L, Ollila J, Nagy B, Vihinen M, et al. Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion. Leukemia 2001; 15:1721 - 8; http://dx.doi.org/10.1038/sj.leu.2402282; PMID: 11681413
   PubMed Web of Science ®Google Scholar
• Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, Gonelli A, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107:4122 - 9; http://dx.doi.org/10.1182/blood-2005-11-4465; PMID: 16439677
   PubMed Web of Science ®Google Scholar
• Coll-Mulet L, Iglesias-Serret D, Santidrián AF, Cosialls AM, de Frias M, Castaño E, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107:4109 - 14; http://dx.doi.org/10.1182/blood-2005-08-3273; PMID: 16439685
   PubMed Web of Science ®Google Scholar
• Kojima K, Konopleva M, McQueen T, O’Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108:993 - 1000; http://dx.doi.org/10.1182/blood-2005-12-5148; PMID: 16543464
   PubMed Web of Science ®Google Scholar
• Secchiero P, Corallini F, Gonelli A, Dell’Eva R, Vitale M, Capitani S, et al. Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 2007; 100:61 - 9; http://dx.doi.org/10.1161/01.RES.0000253975.76198.ff; PMID: 17138942
   PubMed Web of Science ®Google Scholar
• Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008; 111:1584 - 93; http://dx.doi.org/10.1182/blood-2007-09-112698; PMID: 17971485
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48:198 - 206; http://dx.doi.org/10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; PMID: 7237385
   PubMed Web of Science ®Google Scholar
• Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114:2589 - 97; http://dx.doi.org/10.1182/blood-2009-05-224071; PMID: 19643983
   PubMed Web of Science ®Google Scholar
• Larramendy ML, Niini T, Elonen E, Nagy B, Ollila J, Vihinen M, et al. Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis. Haematologica 2002; 87:569 - 77; PMID: 12031912
   PubMed Web of Science ®Google Scholar
• Casas S, Nagy B, Elonen E, Aventín A, Larramendy ML, Sierra J, et al. Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leuk Lymphoma 2003; 44:1935 - 41; http://dx.doi.org/10.1080/1042819031000119299; PMID: 14738146
   PubMed Web of Science ®Google Scholar
• Grasemann C, Gratias S, Stephan H, Schüler A, Schramm A, Klein-Hitpass L, et al. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene 2005; 24:6441 - 9; PMID: 16007192
   PubMed Web of Science ®Google Scholar
• Paderova J, Orlic-Milacic M, Yoshimoto M, da Cunha Santos G, Gallie B, Squire JA. Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses. Cancer Genet Cytogenet 2007; 179:102 - 11; http://dx.doi.org/10.1016/j.cancergencyto.2007.08.014; PMID: 18036396
   PubMed Web of Science ®Google Scholar
• Ageberg M, Gullberg U, Lindmark A. The involvement of cellular proliferation status in the expression of the human proto-oncogene DEK. Haematologica 2006; 91:268 - 9; PMID: 16461319
   PubMed Web of Science ®Google Scholar
• Garçon L, Libura M, Delabesse E, Valensi F, Asnafi V, Berger C, et al. DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Leukemia 2005; 19:1338 - 44; http://dx.doi.org/10.1038/sj.leu.2403835; PMID: 15973457
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al, International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446 - 56; http://dx.doi.org/10.1182/blood-2007-06-093906; PMID: 18216293
   PubMed Web of Science ®Google Scholar
• Xu W, Li JY, Wu YJ, Yu H, Shen QD, Tian T, et al. CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. Leuk Res 2009; 33:237 - 43; http://dx.doi.org/10.1016/j.leukres.2008.06.026; PMID: 18674817
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang Y, Zheng W, Wu Y, Qiao C, Fan L, et al. Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008; 32:1491 - 8; http://dx.doi.org/10.1016/j.leukres.2008.02.005; PMID: 18359082
   PubMed Web of Science ®Google Scholar
• Dong HJ, Zhou LT, Zhu DX, Wang DM, Fang C, Zhu HY, et al. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13). Ann Hematol 2011; 90:709 - 17; http://dx.doi.org/10.1007/s00277-010-1125-8; PMID: 21113594
   PubMed Web of Science ®Google Scholar
• Qiu HX, Xu W, Cao XS, Zhou M, Shen YF, Xu YL, et al. Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: a prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation. Leuk Lymphoma 2008; 49:1887 - 92; http://dx.doi.org/10.1080/10428190802308710; PMID: 18949612
   PubMed Web of Science ®Google Scholar